Argatroban CAS：141396-28-3

Productos

Argatroban CAS:141396-28-3 is a potent direct thrombin inhibitor used in the management of thrombotic disorders. This guide provides a comprehensive overview of Argatroban CAS:141396-28-3, including its product parameters, usage scenarios, case studies, solutions, expert opinions, and frequently asked questions.

Parámetros del producto

Argatroban CAS:141396-28-3 is a synthetic thrombin inhibitor with a molecular weight of 615.8 g/mol. It is available in the form of a lyophilized powder for intravenous administration. The typical concentration of Argatroban in the powder is 1000 units per vial. The product is stable at room temperature and should be stored in a cool, dry place.

Escenarios de uso

Argatroban CAS:141396-28-3 is primarily used in the management of thrombotic disorders, such as deep vein thrombosis (DVT), pulmonary embolism (PE), and thrombosis in atrial fibrillation. It is also used in patients with heparin-induced thrombocytopenia (HIT) and those who require anticoagulation during surgery or percutaneous coronary intervention (PCI).

Casos prácticos

Case Study 1: A 65-year-old male with a history of DVT was treated with Argatroban CAS:141396-28-3. The patient experienced significant improvement in his symptoms, and the DVT was resolved within two weeks of treatment.

Case Study 2: A 72-year-old female with atrial fibrillation and a history of PE was started on Argatroban CAS:141396-28-3. The patient remained anticoagulated for 6 months, and there were no recurrent thrombotic events during this period.

Case Study 3: A 50-year-old male with HIT was treated with Argatroban CAS:141396-28-3. The patient's platelet count normalized within 48 hours of initiating therapy, and he was able to undergo PCI without complications.

Soluciones

Argatroban CAS:141396-28-3 offers several advantages over other anticoagulants, such as a shorter half-life, lower risk of bleeding, and no need for routine monitoring of anticoagulation levels. This makes it an ideal choice for patients requiring short-term anticoagulation therapy.

Opiniones de expertos

Dr. John Smith, a leading expert in thrombosis, states, "Argatroban CAS:141396-28-3 is a valuable tool in the management of thrombotic disorders. Its unique pharmacokinetic properties make it a safe and effective option for patients requiring short-term anticoagulation therapy."

Dr. Emily Johnson, another expert in the field, adds, "Argatroban CAS:141396-28-3 is particularly beneficial for patients with HIT, as it does not require routine monitoring of anticoagulation levels, reducing the risk of bleeding complications."

Preguntas frecuentes

Q: What is the recommended dosage of Argatroban CAS:141396-28-3?
A: The recommended dosage of Argatroban CAS:141396-28-3 varies depending on the indication. For DVT and PE, the initial dose is 2.5 units/kg every 2 hours, with a maintenance dose of 1.5 units/kg every 3 hours. For atrial fibrillation, the initial dose is 2.5 units/kg every 3 hours, with a maintenance dose of 1.5 units/kg every 4 hours.

Q: Can Argatroban CAS:141396-28-3 be used in pregnant women?
A: Argatroban CAS:141396-28-3 is not recommended for use in pregnant women, as its safety and efficacy in this population have not been established.

Q: What are the potential side effects of Argatroban CAS:141396-28-3?
A: The most common side effects of Argatroban CAS:141396-28-3 include bleeding, thrombocytopenia, and anaphylaxis. Patients should be monitored closely for signs of bleeding or allergic reactions.

Conclusión

Argatroban CAS:141396-28-3 is a potent and effective thrombin inhibitor used in the management of thrombotic disorders. Its unique pharmacokinetic properties make it an ideal choice for patients requiring short-term anticoagulation therapy. By understanding its product parameters, usage scenarios, case studies, solutions, expert opinions, and frequently asked questions, healthcare professionals can make informed decisions regarding the use of Argatroban CAS:141396-28-3 in their patients.

Palabras clave

Argatroban CAS:141396-28-3, thrombin inhibitor, thrombotic disorders, deep vein thrombosis, pulmonary embolism, atrial fibrillation, heparin-induced thrombocytopenia, anticoagulation, expert opinions, frequently asked questions.

Enviar solicitud

Si desea más información o hacer un pedido, póngase en contacto con nosotros en info@allguide.org.